Clinical trials
Relapsed or Refractory Hematologic Malignancies clinical trials
Below are recruiting relapsed or refractory hematologic malignancies clinical trials, each written for real people, not researchers. We’re tracking 1,319 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07861971Recruiting
Sports-inspired coaching for young adults in cancer remission
This study tests a sports-inspired coaching program for young adults who have finished cancer treatment and are in remission. It aims to see if the program is feasible and helpful for improving well-being.
MarseilleAges 18 years+ - NCT05833763RecruitingPhase 2
Glosfitamab plus pirtobrutinib for mantle cell lymphoma after BTK drugs
This Phase 2 trial tests how well two anti-cancer medicines—glofitamab and pirtobrutinib—work for mantle cell lymphoma (MCL) that has not responded well to prior BTK inhibitor therapy. It may help by shrinking the lymphoma after earlier treatment and checking how safe the combination is for people with similar disease history.
Parkville, VictoriaAges 18 years+ - NCT07874100Recruiting
Personalized treatment for acute myeloid leukemia
This study looks for markers in your blood to help doctors choose the most effective treatment, especially a drug called venetoclax. By understanding your leukemia at a very detailed level, they hope to improve outcomes for you and others.
MilanAges 18 years+ - NCT05969041RecruitingPhase 1
Early-phase drug trial for advanced epithelial cancers
This Phase 1 study tests a new drug (MT-302) in adults with advanced or metastatic epithelial cancers that have worsened or stopped responding to standard treatment. The goal is to see how the drug works and whether it is safe for people with limited options.
Darlinghurst, New South WalesAges 18 years+ - NCT05243212RecruitingPhase 1/Phase 2
CAR-T cell therapy for multiple myeloma
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
Ramat GanAges 18 years+ - NCT05204459Recruiting
MRI and eye-scan study for MS and related conditions
This trial uses brain MRI and eye imaging tests to study research markers in people with multiple sclerosis (MS) and related neurologic conditions. It may help researchers better understand these diseases and how they change over time.
Los Angeles, CaliforniaAges 18 years+ - NCT06262386Recruiting
Predicting lung cancer return after surgery
This study tests a new way to predict if non-small cell lung cancer will return after surgery. You will give blood samples to look for cancer cells, and the team will build a model to help plan better follow-up care.
Taoyuan CityAges 20–90 - NCT06277427Recruiting
CAR-T cell therapy for refractory vasculitis and lupus nephritis
This trial tests a new type of cell therapy called CAR-T cells that target BCMA (a protein on certain immune cells) for people with two autoimmune diseases: ANCA-associated vasculitis and lupus nephritis. It is for patients whose disease has not responded to standard treatments or has come back after initial improvement.
Wuhan, HubeiAges 18–70 - NCT05602610Recruiting
Predicting relapse risk after visceral leishmaniasis
This study looks at a prognostic score to predict whether visceral leishmaniasis (VL) will come back after treatment. If you qualify, your information may help doctors estimate relapse risk and plan follow-up more safely.
GonderAges 12 years+ - NCT06128837RecruitingPhase 3
Study of a new drug for recurrent small cell lung cancer
This trial tests a drug called LY01610 for people with small cell lung cancer that has returned after initial chemotherapy. It may offer a new treatment option for those whose cancer progressed within 6 months of their last treatment.
BeijingAges 18 years+ - NCT06339775RecruitingPhase 4
Blinatumomab for leukemia relapse after a stem cell transplant
This trial tests the drug blinatumomab for people whose B-cell acute lymphoblastic leukemia (B-ALL) has come back after a stem cell transplant. The goal is to see if blinatumomab can safely treat the relapse.
Zhenzhou, HenanAges Up to 65 years - NCT06340204RecruitingPhase 1
Weekly liposomal irinotecan for advanced Ewing sarcoma
This trial tests a weekly dose of a chemotherapy drug wrapped in liposomes (tiny fat bubbles) for people with Ewing sarcoma that has come back or not responded to standard treatments. The goal is to see if this new form of the drug can help when other options have stopped working.
Jina, ShandongAges 8–40 - NCT05080556RecruitingPhase 2
Adaptive chemotherapy for ovarian cancer after platinum and PARP
This trial tests a personalized (adaptive) chemotherapy plan for people with certain types of ovarian/fallopian tube/peritoneal cancer who already had platinum chemotherapy and a PARP inhibitor. It’s for patients whose cancer came back after (or still responds to) prior platinum treatment and may help delay disease progression.
LondonAges 18 years+ - NCT06195800Recruiting
Biomarkers after stem cell transplant for neurological diseases
This trial looks at biomarkers (biological signs in your blood) in people with immune-mediated neurological diseases. It compares those getting a stem cell transplant to those on high-efficacy MS treatments to understand how these therapies work.
Sheffield, EnglandAges 16 years+ - NCT06375161RecruitingEarly Phase 1
CAR-T cells for relapsed B-cell cancers
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
Shanghai, Shanghai MunicipalityAges 4 months–1.3 years - NCT06124287Recruiting
Can MRI predict Crohn's relapse after stopping biologics?
This study looks at whether MRI scans can predict when Crohn's disease will come back after stopping biologic medications. If you are in remission and recently stopped a biologic, researchers want to see if your MRI results can help understand your risk of relapse.
LondonAges 16 years+ - NCT07851636Recruiting
Fast genetic testing to guide treatment for rare brain tumors
This trial tests a new way to pick treatments for rare brain tumors that have come back. Doctors will quickly analyze your tumor's genes and test drugs in the lab to find the best option for you.
Washington D.C., District of ColumbiaAges Up to 45 years - NCT05536089Recruiting
Testing blood methylation to predict colorectal cancer relapse
This trial checks a blood test for “ctDNA methylation” to see who may be at higher risk of colorectal cancer returning after surgery. It may help doctors better judge whether adjuvant chemotherapy is working or needed.
Hangzhou, ZhejiangAges 18 years+ - NCT04625907RecruitingPhase 1/Phase 2
Study testing treatment options for children and adults with RMS
This study tests different treatment approaches for rhabdomyosarcoma (RMS) in children and adults, including newly diagnosed high-risk cases, people needing radiotherapy, and people whose RMS has returned. It’s designed to find safer dosing and more effective therapy while checking whether participants can proceed based on health and timing requirements.
BrisbaneAges Any age - NCT05310591RecruitingPhase 1/Phase 2
Study anti-PD1 treatment with Kymriah re-dosing for leukemia
This Phase 1/2 trial studies giving an anti-PD1 antibody (like pembrolizumab or nivolumab) along with a second Kymriah (tisagenlecleucel) infusion in children and young adults whose B-cell leukemia is coming back or their Kymriah effect has faded. It may help the new immune treatment work better after the first Kymriah.
BordeauxAges 1–25 - NCT04050345Recruiting
Blood test to spot DNA changes after early colon cancer surgery
This study checks a “cell-free tumor DNA” blood test to see if cancer mutations can predict relapse after surgery for early colorectal cancer. If results look risky, they may help guide closer follow-up and future treatment decisions.
Milton Keynes, BuckinghamshireAges 18 years+ - NCT07826689RecruitingPhase 1/Phase 2
Oral pill for relapsing multiple sclerosis
This study tests an experimental oral drug, PRO-1562, in two parts: first in healthy volunteers to check safety, then in people with relapsing multiple sclerosis to see if it can reduce disease activity. It may offer a new, convenient treatment option.
Adelaide, South AustraliaAges 18–65 - NCT06086197RecruitingPhase 2
A drug combo for early relapsed or refractory DLBCL
This trial tests a combination of chemotherapy drugs for people with a type of lymphoma called diffuse large B-cell lymphoma that has either come back early or never fully responded to first treatment. The goal is to see if this drug combination can help control the lymphoma.
Hangzhou, ZhejiangAges 18 years+ - NCT05772559Recruiting
Study of AML genes and drug response in young patients
This trial looks at how childhood, teen, and young adult acute myeloid leukemia (AML) changes at the genetic level and how cells respond to multiple drugs. It may help doctors understand which treatments work best and how leukemia interacts with supportive cells in the bone marrow.
AmiensAges Up to 25 years
Hear when a new Relapsed or Refractory Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory hematologic malignancies?
- Yes. Clin2 currently lists 1,319 recruiting relapsed or refractory hematologic malignancies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory hematologic malignancies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory hematologic malignancies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory B-cell Malignancies
- Relapsed/Refractory Hematological Malignancies
- Relapsed/Refractory Multiple Myeloma
- Relapsed/Refractory Acute Myeloid Leukemia
- Relapsed or Refractory Multiple Myeloma
- Relapsed or Refractory Multiple Myeloma (RRMM)
- Relapsed/Refractory B-cell Lymphoma
- Non-Hodgkin Lymphoma Refractory/ Relapsed
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.